The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
Signed informed consent
Patient with histologically proven TNBC
Indication for neo-adjuvant chemo-immunotherapy treatment
Age between 18 and 75
Pregnant or breast-feeding women
Contraindication to immunotherapy
Inflammatory breast cancer (T4d)
Metastatic patients
Single group
Imaging assessment
Other interventionThe patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC).
concordance of the response between radiological assessement and histological response
Click on the lead sponsor to view all of their trials.
